GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (LTS:0A45) » Definitions » Valuation Rank

Moderna (LTS:0A45) Valuation Rank


View and export this data going back to 2020. Start your Free Trial

What is Moderna Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Moderna Valuation Rank Related Terms

Thank you for viewing the detailed overview of Moderna's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Moderna (LTS:0A45) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (LTS:0A45) » Definitions » Valuation Rank
Comparable Companies
BNTX BGNE ALNY SGEN BMRN RPRX LEGN INCY UTHR SRPT OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 HKSE:02269 XBRU:ARGX SZSE:300122 OCSE:GMAB XKRX:068270
Traded in Other Exchanges
MRNA:USA MRNA:Peru MRNA:Mexico 0QFd:UK 0QF:Germany M1RN34:Brazil MRNA:Austria
Address
200 Technology Square, Cambridge, MA, USA, 02139
Website
https://www.modernatx.com
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.